An observational study in Portal Hypertension, sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-25.
Sponsored by Hepatopancreatobiliary Surgery Institute of Gansu Province · Observational
Among 10 studies in Hypertension, Portal by Hepatopancreatobiliary Surgery Institute of Gansu Province — 3 open to participants now, 3 under way, none of them phase 3. Hypertension, Portal · Hepatopancreatobiliary Surgery Institute of Gansu Province.
Among the 10 studies in Hypertension, Portal by Hepatopancreatobiliary Surgery Institute of Gansu Province, this one is one of 3 that started in 2023, is one of 5 observational ones, and was the 5th registered.
375 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 150 across 135 observational studies indexed under Hypertension, Portal.
Browse Hypertension, Portal studies →3 of the 10 studies in Hypertension, Portal by Hepatopancreatobiliary Surgery Institute of Gansu Province are open now, in 1 country. Each count lists the studies.
Of the 69 Hypertension, Portal studies recruiting now, 33 (48%) set no upper age limit and 13 (19%) stop at 75 or younger; 1 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →10 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2023.
Median enrollment 4 across the 1 interventional studies, 1,000 across the 9 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
Hepatopancreatobiliary Surgery Institute of Gansu Province is the lead sponsor of 44 studies on the registry; 8 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hypertension, Portal by Hepatopancreatobiliary Surgery Institute of Gansu Province, from their registry updates:
Nothing recorded among them since 2026-09-25.
Portal hypertension contributed to the main complications of liver cirrhosis. Currently, hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal pressure in patients with cirrhosis. However, the practice of HVPG is limited to require the extensive experience and highly specialized centers. In recent years, non-invasive methods were proposed to predict the degree of cirrhotic portal hypertension. Of them, liver stiffness measured by FibroScan had shown good performance for predicting clinically significant portal hypertension. However, the correlation between liver stiffness and HVPG was poor when HVPG was more than 12mmHg. Since the spleen was stiffer than the liver, the current vibration-controlled transient elastography examination is dedicated to the liver, rather than the spleen. Very recently, a novel spleen-dedicated stiffness measured by FibroScan was proposed. The prospective, multicenter study aims to evaluate the correlation between SS (measured by the novel FibroScan) and HVPG, and further develop a novel model based on SS for predicting the liver decompensation in patients with compenstaed cirrhosis.
Portal hypertension contributed to the main complications of liver cirrhosis. Currently, hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal pressure in patients with cirrhosis. However, the practice of HVPG is limited to require the extensive experience and highly specialized centers. In recent years, non-invasive methods were proposed to predict the degree of cirrhotic portal hypertension. Of them, liver stiffness measured by FibroScan had shown good performance for predicting clinically significant portal hypertension. However, the correlation between liver stiffness and HVPG was poor when HVPG was more than 12mmHg. Since the spleen was stiffer than the liver, the current vibration-controlled transient elastography examination is dedicated to the liver, rather than the spleen. Very recently, a novel spleen-dedicated stiffness measured by FibroScan was proposed. The prospective, multicenter study (CHESS2105 leaded by The First Hospital of Lanzhou University and Shulan (Hangzhou) Hospital) aims to evaluate the correlation between SS (measured by the novel FibroScan) and HVPG, and further develop a novel model based on SS for predicting the liver decompensation in patients with compenstaed cirrhosis.
Patients was fulfilled the diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
Diagnostic Test: Hepatic venous pressure gradient
Patients were fulfilled diagnosis of cirrhosis based on radiological, histological features of liver cirrhosis.
Diagnostic Test: Hepatic venous pressure gradient
All patients underwent measurement of HVPG under local anesthesia.
Accuracy of a new model based on spleen stiffness (kPa) measured by transient elastography for diagnosing portal hypertension.
In HVPG (mmHg) as reference method in evaluating portal pressure measured by intervention specialist , to develop a new model based on spleen stiffness (kPa) measured by transient elastography and evaluate the accuracy in diagnosing portal hypertension.
Time frame: 1 years
Accuracy of model based on spleen stiffness (kPa) measured by transient elastography for predicting incidence of liver decompensation in patients with compenstaed cirrhosis
To develop a novel model based on spleen stiffness (kPa) measured by transient elastography for predicting the incidence of liver decompensation in patients with compenstaed cirrhosis.
Time frame: 3 years
Plan to share: Undecided
This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hepatopancreatobiliary Surgery Institute of Gansu Province